Danish pharmaceutical giant Novo Nordisk has announced it is partnering with US biotech Vivtex Corporation in a deal worth up to $2.1 billion to develop next-generation oral biologic medicines for obesity and diabetes. The partnership will specifically focus on developing technologies that could allow biologic medicines, which are typically administered by injection due to poor […]